CohBar added to Russell 2000 Index » 09:0606/3006/30/20
CohBar was added to the…
CohBar was added to the US small-cap Russell 2000 Index during the 2020 Russell Indexes reconstitution. The company also sold shares of common stock through its previously disclosed ATM offering with net proceeds of approximately $4.4M in funding through the June 26th reconstitution.
|Over a week ago|
CohBar to host business news update conference call » 08:2206/1606/16/20
Conference call to be …
Conference call to be held on June 16 at 5pm.
|Over a month ago|
CohBar initiated with a Buy at Brookline » 09:5305/2705/27/20
Brookline analyst Kumaraguru Raja initiated coverage of CohBar with a Buy rating and $10 price target.
CohBar COO Jon Stern to step down » 09:0205/1305/13/20
CohBar announced that Jon…
CohBar announced that Jon Stern plans to step down from his role as the company's COO, effective May 31, 2020. Since joining the company in 2012, Mr. Stern has served in various executive roles including chief strategic officer and CEO. He will remain actively involved as a member of the company's board of directors.
CohBar to target COVID-19 associated ARDS with apelin receptor agonist peptides » 09:1305/0505/05/20
CohBar announced that it…
CohBar announced that it has initiated testing of its CB5064 analogs in preclinical models of ARDS, to assess their potential as therapeutics for coronavirus disease 2019 associated ARDS. In preclinical studies to date, these peptides have demonstrated the ability to activate the apelin receptor, a cell signaling pathway that published preclinical studies have shown can reduce the severity of acute lung injury by reducing lung fluid accumulation, hypoxemia, and cytokine secretion, which occur in COVID-19 associated ARDS, and lead to downstream injury to the kidney, heart, and other organs. COVID-19 associated ARDS is a new target for the company's ongoing program of CB5064 analogs. These analogs previously demonstrated efficacy in diet induced obese or DIO mice, a widely used model of type 2 diabetes, leading to significant reduction in body weight, adiposity, and improvement in insulin sensitivity, as presented by CohBar at the American Diabetes Association national meeting in 2019. Published clinical reports show that obesity and diabetes are major underlying risk factors in severe COVID-19, and are associated with significantly increased mortality.
CohBar announces acceptance of abstract on antifibrotic peptides » 08:3404/1404/14/20
CohBar announced acceptance of a late-breaking abstract as a poster presentation at the American Thoracic Society 2020 International Conference, which was scheduled to be held May 15-20 in Philadelphia, PA, and has since been cancelled. American Thoracic Society is currently exploring options for providing select elements of the conference content including ePosters in an online format later this year. CohBar's ePoster will contain data on a family of novel analogs of a peptide encoded in mitochondrial DNA, demonstrating beneficial effects in mouse models of Idiopathic Pulmonary Fibrosis. In December 2019, CohBar announced preclinical data confirming the therapeutic potential of a novel CohBar peptide, MBT2. In a preclinical animal model of IPF, MBT2 reduced lung fibrosis, inflammation, and collagen levels after 14 days of administration. IPF is a chronic, progressive, debilitating and usually fatal lung disease that results in the scarring of the lungs, also known as fibrosis, and represents a high unmet medical need affecting approximately 100,000 patients in the U.S.
|Over a quarter ago|
CohBar anticipates delay in completion of CB4211 Phase 1b study » 09:1903/3003/30/20
CohBar announced that it…
CohBar announced that it is anticipating delays in the completion of its CB4211 Phase 1b study for NASH and obesity. This delay is a result of a pause by some of the company's clinical research organization partners in all of their activities related to the study in response to the COVID-19 pandemic and the advice of the CDC and local authorities. Given the uncertainties around this unprecedented pandemic and its impact on the Phase 1b clinical study activities, including enrollment of subjects, the company is unable to provide additional guidance at this time.
CohBar discovers novel peptide inhibitors of CXCR4 » 09:0801/0801/08/20
CohBar announced the…
CohBar announced the discovery of a series of novel mitochondrial peptide analogs with potent in vitro activity as selective inhibitors of C-X-C Chemokine Receptor Type 4 and with preliminary in vivo efficacy in a mouse model of melanoma, including substantial reduction in tumor growth as compared to control animals. CXCR4 is a key regulatory receptor involved in tumor growth, invasion, angiogenesis, metastasis, and resistance to therapy. Novel peptide analogs of a mitochondrially encoded peptide demonstrated potent and selective inhibition of human CXCR4 receptor in cell-based assays, with IC50 values in the low nanomolar concentration range. In a difficult-to-treat in vivo mouse model of melanoma, the B16F10 syngeneic tumor model, the combination of an analog of MBT5 administered subcutaneously with the chemotherapeutic temozolomide showed enhanced antitumor activity, reducing tumor growth after 11 days by 61% compared to control animals. The reduction in tumor growth produced by the combination exceeded the effect of either temozolomide used as a single agent, which reduced tumor growth by 38% compared to control, or the murine checkpoint inhibitor anti-PD-1 antibody, which had no effect on tumor growth in this model. CohBar plans to further explore the efficacy of this new family of peptides in additional animal models with the goal of identifying a new clinical development MBT candidate. CXCR4 is overexpressed in more than 75% of cancers and high levels of the receptor are associated with poor survival prognosis. Inhibition of the CXCR4 receptor has been shown to mobilize immune cells, enhance the effects of chemotherapy and immunotherapy in various cancers, and reduce the development of metastatic tumors by blocking the ability of tumor cells to evade immune surveillance. CXCR4 also regulates the homing and retention of hematopoietic stem cells and malignant cells in the bone marrow.
CohBar announces preclinical data on novel peptide in therapeutic model of IPF » 09:1312/1612/16/19
CohBar announced new…
CohBar announced new preclinical data confirming the therapeutic potential of a novel CohBar peptide in a preclinical model of Idiopathic Pulmonary Fibrosis. New data show the peptide positively affected all of the efficacy parameters evaluated in the study, including reduction in lung fibrosis, inflammation, and collagen levels after 14 days of administration in a therapeutic mouse model of IPF. IPF is a chronic, progressive, debilitating and usually fatal lung disease that results in the scarring of the lungs, also known as fibrosis, and represents a high unmet medical need affecting approximately 100,000 patients in the U.S. This was a therapeutic study where treatment commenced after fibrosis was established by administration of bleomycin. Previously, positive results were observed in a prophylactic model where treatment began immediately after administration of bleomycin. New in vitro data also demonstrate that CohBar's peptide decreases the production of pro-collagen in cultured human fibroblasts, and inhibits the process of conversion of healthy lung epithelial cells to pathological pro-fibrotic cells. Collectively, the new data confirm the previously announced positive data obtained in a prophylactic mouse model of lung fibrosis.
CohBar completes Phase 1a, initiates Phase 1b stage of CB4211 trial » 09:1411/0511/05/19
CohBar announced the…
CohBar announced the completion of the Phase 1a stage of the company's ongoing Phase 1a/1b study evaluating the safety, tolerability, and activity of CB4211, and the initiation of recruitment for the Phase 1b stage. CB4211 is under development as a potential treatment for nonalcoholic steatohepatitis and obesity, and is the first therapeutic candidate based on a mitochondrial-derived peptide to enter clinical testing. The Phase 1b stage of the ongoing study is designed to assess the safety, tolerability, and activity of CB4211 in obese subjects with NAFLD. The double-blind, placebo-controlled evaluation will be conducted over four weeks in twenty patients with ten patients receiving CB4211 and ten receiving placebo. Assessments will include changes in liver fat as determined by MRI-PDFF, body weight, and biomarkers relevant to NASH and obesity. Results from both stages of the study are anticipated in mid-2020. An estimated 75 million U.S. adults have NAFLD, and as many as 35% of them, or 26 million, will progress to NASH. Approximately 20% of people with NASH will go on to develop fibrosis of the liver, leading to cirrhosis and an increased risk of liver failure and cancer. There are no approved treatments for the disease